Gateway Investment Advisers LLC Grows Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Gateway Investment Advisers LLC lifted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 19.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 7,383 shares of the biopharmaceutical company’s stock after acquiring an additional 1,222 shares during the quarter. Gateway Investment Advisers LLC’s holdings in Alnylam Pharmaceuticals were worth $1,737,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the stock. Geode Capital Management LLC grew its stake in shares of Alnylam Pharmaceuticals by 3.2% during the 3rd quarter. Geode Capital Management LLC now owns 2,147,203 shares of the biopharmaceutical company’s stock valued at $589,209,000 after acquiring an additional 66,928 shares during the period. Charles Schwab Investment Management Inc. grew its stake in shares of Alnylam Pharmaceuticals by 3.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 487,348 shares of the biopharmaceutical company’s stock valued at $134,035,000 after acquiring an additional 16,756 shares during the period. Avoro Capital Advisors LLC grew its stake in shares of Alnylam Pharmaceuticals by 33.3% during the 2nd quarter. Avoro Capital Advisors LLC now owns 400,000 shares of the biopharmaceutical company’s stock valued at $97,200,000 after acquiring an additional 100,000 shares during the period. Swiss National Bank grew its stake in shares of Alnylam Pharmaceuticals by 0.3% during the 3rd quarter. Swiss National Bank now owns 375,400 shares of the biopharmaceutical company’s stock valued at $103,246,000 after acquiring an additional 1,000 shares during the period. Finally, Eagle Asset Management Inc. grew its stake in shares of Alnylam Pharmaceuticals by 25.7% during the 3rd quarter. Eagle Asset Management Inc. now owns 309,589 shares of the biopharmaceutical company’s stock valued at $85,889,000 after acquiring an additional 63,385 shares during the period. 92.97% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, EVP Tolga Tanguler sold 1,469 shares of the stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total transaction of $368,689.62. Following the transaction, the executive vice president now owns 13,191 shares of the company’s stock, valued at approximately $3,310,677.18. This represents a 10.02 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CMO Pushkal Garg sold 1,752 shares of the stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $251.00, for a total value of $439,752.00. Following the transaction, the chief marketing officer now directly owns 15,705 shares in the company, valued at $3,941,955. The trade was a 10.04 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 10,122 shares of company stock worth $2,540,455 over the last quarter. Company insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Stock Performance

NASDAQ:ALNY opened at $246.27 on Friday. The stock’s fifty day moving average is $246.62 and its 200 day moving average is $259.70. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $304.39. The firm has a market capitalization of $31.76 billion, a PE ratio of -94.00 and a beta of 0.34. The company has a debt-to-equity ratio of 31.64, a quick ratio of 2.69 and a current ratio of 2.75.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The company had revenue of $500.90 million during the quarter, compared to the consensus estimate of $532.91 million. During the same quarter in the previous year, the firm earned $1.15 EPS. The business’s revenue for the quarter was down 33.3% compared to the same quarter last year. On average, sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -2.21 earnings per share for the current year.

Analyst Ratings Changes

ALNY has been the subject of a number of recent research reports. Needham & Company LLC reiterated a “buy” rating and set a $320.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Monday, January 13th. HC Wainwright restated a “buy” rating and issued a $400.00 price target on shares of Alnylam Pharmaceuticals in a research note on Monday, January 13th. Sanford C. Bernstein dropped their price target on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating for the company in a research note on Tuesday, January 7th. TD Cowen upped their price target on Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. Finally, Raymond James upped their price target on Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the stock an “outperform” rating in a research note on Friday, November 1st. One investment analyst has rated the stock with a sell rating, six have given a hold rating and nineteen have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $298.61.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.